-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Traders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc.
Traders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc.
NEW YORK, NY / ACCESSWIRE / August 25, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Q BioMed.
Mark had the pleasure of recently conducting the Interview featuring Denis D Corin, CEO and Chairman Q BioMed Inc. (OTCQB:QBIO). Mr. Roberts diligently focused on questions he thought would be on the minds of most current and potential future shareholders. See interview highlights below.
Access this interview in its entirety at
Denis D Corin
CEO and Chairman
Mr. Denis D. Corin is Chief Executive Officer and Chairman of the Board. Mr. Corin is an experienced public company executive and management consultant. He has worked almost exclusively in the biomedical field for over 13 years from large pharma and diagnostic companies to small innovative biotech. He has served in various senior executive roles and has been instrumental in building and restructuring businesses. Mr. Corin has raised millions of dollars in development capital to advance businesses. Mr. Corin also served as a Management Consultant to the executives and board of TapImmune Inc. (NASD:TPIV), a clinical stage immune -oncology company through 2014. He holds a Bachelors Degree majoring in both Economics and Marketing & Advertising Management from the University of Natal, South Africa.
Interview Highlights:
Traders News Source Editor Mark Roberts covers Strontium89 sales revenue, which of the preclinical stage products are expected to develop the fastest, QBIO portfolio of patents, patents pending and much more in this interview.
Access this interview in its entirety at
About Q BioMed Inc.
Q BioMed Inc is a biotech acceleration and commercial stage company. Q BioMed is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need.
Please visit and sign up for regular updates.
Q BioMed Media Contact:
Denis Corin
CEO
Investor Relations:
Keith Pinder
+1(404) 995-6671
ir@qbiomed.com
About Traders News Source (TNS)
Traders News Source is a leading independent equity research and corporate access firm focused on finding and reporting on the next hot stocks and market sectors prior to a significant move. TNS is also a financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. Our C-level interviews answer some of the hard-hitting questions that rest on the minds of most current and future shareholders. TNS C-level interviews provide valuable insights into the operations and management direction of some of the most promising small and mid-cap publicly traded companies. To review TNS disclosure statement please visit:
Media Contact
Traders News Source
Mark Roberts, Senior Editor/Interviewer Editor@TradersNewsSource.com
or Call Paul Lipp, President TNS LLC at +1-810-618-1023
SOURCE: Traders News Source LLC
View source version on accesswire.com:
NEW YORK, NY / ACCESSWIRE / August 25, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Q BioMed.
纽约,NY/ACCESSWIRE/2022年8月25日/交易商新闻来源,一家领先的独立股票研究和企业准入公司,专注于中小型上市公司,最近发布了对Q BioMed的新的C级采访。
Mark had the pleasure of recently conducting the Interview featuring Denis D Corin, CEO and Chairman Q BioMed Inc. (OTCQB:QBIO). Mr. Roberts diligently focused on questions he thought would be on the minds of most current and potential future shareholders. See interview highlights below.
马克很高兴最近采访了Q BioMed Inc.(OTCQB:QBIO)首席执行官兼董事长丹尼斯·D·科林。罗伯茨勤奋地专注于他认为大多数当前和未来潜在股东都会考虑的问题。请看下面的采访要点。
Access this interview in its entirety at
访问此访谈全文,请访问
Denis D Corin
丹尼斯·D·科林
CEO and Chairman
首席执行官兼董事长
Mr. Denis D. Corin is Chief Executive Officer and Chairman of the Board. Mr. Corin is an experienced public company executive and management consultant. He has worked almost exclusively in the biomedical field for over 13 years from large pharma and diagnostic companies to small innovative biotech. He has served in various senior executive roles and has been instrumental in building and restructuring businesses. Mr. Corin has raised millions of dollars in development capital to advance businesses. Mr. Corin also served as a Management Consultant to the executives and board of TapImmune Inc. (NASD:TPIV), a clinical stage immune -oncology company through 2014. He holds a Bachelors Degree majoring in both Economics and Marketing & Advertising Management from the University of Natal, South Africa.
丹尼斯·D·科林先生是首席执行官兼董事会主席。科林先生是一位经验丰富的上市公司高管和管理顾问。他几乎完全在生物医学领域工作了13年多,从大型制药和诊断公司到小型创新生物技术公司。他曾担任过各种高级管理职位,并在建立和重组业务方面发挥了重要作用。科林已经筹集了数百万美元的发展资金,用于推动业务发展。科林先生还曾担任TapImmune Inc.(NASD:TPIV)高管和董事会的管理顾问,该公司是一家临床阶段免疫肿瘤学公司,一直到2014年。他拥有南非纳塔尔大学经济学和营销与广告管理专业的学士学位。
Interview Highlights:
面试要点:
Traders News Source Editor Mark Roberts covers Strontium89 sales revenue, which of the preclinical stage products are expected to develop the fastest, QBIO portfolio of patents, patents pending and much more in this interview.
Traders新闻来源编辑Mark Roberts报道了Strontium89的销售收入,在这次采访中,哪些临床前阶段的产品有望开发出最快的QBIO专利组合、正在申请的专利等。
Access this interview in its entirety at
访问此访谈全文,请访问
About Q BioMed Inc.
关于Q BioMed Inc.
Q BioMed Inc is a biotech acceleration and commercial stage company. Q BioMed is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need.
Q BioMed Inc.是一家生物技术加速和商业阶段公司。Q BioMed专注于许可和收购医疗行业被低估的生物医疗资产。Q BioMed致力于为这些目标资产提供所需的战略资源、发展支持和扩张资本,以确保它们满足其发展潜力,使它们能够向需要的患者提供产品。
Please visit and sign up for regular updates.
请访问并注册以定期更新。
Q BioMed Media Contact:
问:BioMed媒体联系人:
Denis Corin
CEO
丹尼斯·科林
首席执行官
Investor Relations:
投资者关系:
Keith Pinder
+1(404) 995-6671
ir@qbiomed.com
基思·平德
+1(404) 995-6671
邮箱:ir@qbied.com
About Traders News Source (TNS)
关于交易商新闻来源(TNS)
Traders News Source is a leading independent equity research and corporate access firm focused on finding and reporting on the next hot stocks and market sectors prior to a significant move. TNS is also a financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. Our C-level interviews answer some of the hard-hitting questions that rest on the minds of most current and future shareholders. TNS C-level interviews provide valuable insights into the operations and management direction of some of the most promising small and mid-cap publicly traded companies. To review TNS disclosure statement please visit:
交易员新闻来源是一家领先的独立股票研究和企业访问公司,专注于在重大举措之前发现和报告下一个热门股票和市场板块。TNS也是一家金融新闻提供商,专注于让投资者直接接触有前途的上市公司的首席执行官和市场专家。我们的C层访谈回答了大多数当前和未来股东心中的一些尖锐问题。TNS C级访谈为一些最有前途的中小型上市公司的运营和管理方向提供了宝贵的见解。要查看TNS披露声明,请访问:
Media Contact
媒体联系人
Traders News Source
交易员新闻来源
Mark Roberts, Senior Editor/Interviewer Editor@TradersNewsSource.com
高级编辑/采访者编辑@TradersNewsSource.com
or Call Paul Lipp, President TNS LLC at +1-810-618-1023
或致电保罗·利普,总裁TNS LLC,电话:+1-810-618-1023
SOURCE: Traders News Source LLC
资料来源:交易员新闻来源有限责任公司
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧